Presentation is loading. Please wait.

Presentation is loading. Please wait.

Omalizumab facilitates rapid oral desensitization for peanut allergy

Published byLiani Jayadi Modified over 6 years ago

Similar presentations

Presentation on theme: "Omalizumab facilitates rapid oral desensitization for peanut allergy"— Presentation transcript:

1 Omalizumab facilitates rapid oral desensitization for peanut allergy
Andrew J. MacGinnitie, MD, PhD, Rima Rachid, MD, Hana Gragg, MPH, Sara V. Little, BA, Paul Lakin, MS, Antonella Cianferoni, MD, Jennifer Heimall, MD, Melanie Makhija, MD, Rachel Robison, MD, R. Sharon Chinthrajah, MD, John Lee, MD, Jennifer Lebovidge, PhD, Tina Dominguez, PA, Courtney Rooney, RN, Megan Ott Lewis, MSN, CRNP, Jennifer Koss, RN, Elizabeth Burke-Roberts, MSN, CPNP, Kimberly Chin, BA, Tanya Logvinenko, PhD, Jacqueline A. Pongracic, MD, Dale T. Umetsu, MD, PhD, Jonathan Spergel, MD, PhD, Kari C. Nadeau, MD, PhD, Lynda C. Schneider, MD  Journal of Allergy and Clinical Immunology  Volume 139, Issue 3, Pages e8 (March 2017) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study enrollment, randomization, procedures, and outcomes. OL, Open label. OL also indicates subjects who were considered to have failed peanut OIT and went on to receive open-label omalizumab. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Highest dose of peanut protein tolerated during initial rapid desensitization. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Changes in immunologic characteristics. Wheal size for peanut SPTs (A) and peanut-specific IgE measurements (B) are shown at baseline and week 31 of the study after 12 weeks off study drug. OL, Open-label. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Omalizumab facilitates rapid oral desensitization for peanut allergy"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.
Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M

Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M
Advances in food allergy in 2015

Advances in food allergy in 2015
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study  John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study  John M. Brehm, MD, MPH, Brooke Schuemann, BS,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Desensitization to Chemotherapeutic Agents

Desensitization to Chemotherapeutic Agents
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Omalizumab facilitates rapid oral desensitization for peanut allergy

Omalizumab facilitates rapid oral desensitization for peanut allergy
A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response  Pooja Varshney, MD, Stacie.

A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response  Pooja Varshney, MD, Stacie.
Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

Similar presentations

Ads by Google